Table 1 Demographic and clinical characteristics of the lupus patient study group
From: Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Demographic and clinical characteristics | Number of SLE patients |
|---|---|
Age, years | 48.1 ± 14.7 |
Sex, female/male | 113/14 |
Renal disease | 37 (29) |
Arthritis | 54 (43) |
Serositis | 38 (30) |
Haematological disorder | 82 (65) |
Neurological disorder | 24 (19) |
Immunological disorder | 119 (94) |
Anti-dsDNA | 40 (38) |
ANA | 104 (82) |
Anti-phospholipid syndrome | 18 (14) |
Low C3 | 27 (22) |
Low C4 | 44 (36) |
Prednisolone <7.5 mg daily | 39 (31) |
Prednisolone >7.5 mg daily | 17 (13) |
Anti-malarials | 82 (65) |
Azathioprine, MTX, or mycophenolate mofetil | 46 (36) |
SLICC/ACR Damage Index, mean ± SD (range) | 0.85 ± 1.2 (0–8) |